Key Takeaways:
A securities class action lawsuit filed against Gossamer Bio, Inc. (NASDAQ: GOSS) alleges the company made misleading statements about its Phase 3 PROSERA study, leading to an 80% collapse in its stock price after the trial’s failure was announced. The lawsuit, filed in the U.S. District Court for the Southern District of California, names Gossamer and a key executive as defendants, with a lead plaintiff deadline of June 1, 2026.
"Generic risk factor language cannot substitute for disclosing specific, known problems that are already affecting a company's operations," said Joseph E. Levi, a partner at Levi & Korsinsky, LLP, one of the firms representing investors. "When a company possesses detailed enrollment data showing a material divergence from stated trial objectives, investors deserve to be informed."
The legal action centers on allegations that Gossamer concealed crucial flaws in its clinical trial design for seralutinib, a drug intended to treat pulmonary arterial hypertension (PAH). According to the complaint, the company failed to disclose that patient enrollment characteristics at its Latin American sites created a high risk of an outsized placebo response, which ultimately compromised the study's primary endpoint. When Gossamer revealed on February 23, 2026, that the PROSERA study had failed, its shares fell from $1.71 to $0.42 in a single day.
The complaint argues that throughout the Class Period, from June 16, 2025, to February 20, 2026, Gossamer's public statements painted an overly positive picture. Management had previously compared its trial to Merck’s successful STELLAR study, noting that "the best performing region was Latin America, and we have actually more patients coming from those same geographies and same sites." However, the lawsuit contends these statements were materially misleading as the company allegedly knew or recklessly disregarded that the Latin American patient population was heavily-treated and lower-risk, predisposing the trial to a high placebo effect that would dilute the drug's observable efficacy.
Multiple law firms, including Rosen Law Firm, Hagens Berman, and Bronstein, Gewirtz & Grossman, have announced investigations or filed suits. The core of the allegations is that Gossamer’s risk disclosures were insufficient. Instead of providing specific warnings about the known geographic enrollment risks, the company allegedly relied on generic, boilerplate language about clinical trial uncertainty.
The lawsuit asserts that as the trial sponsor, Gossamer had access to site-level data and was aware of the enrollment disparities. The subsequent 80% stock drop and a notice from Nasdaq on April 9, 2026, that the company no longer met the minimum bid price requirement, are cited as direct consequences of the alleged misrepresentations.
Investors who purchased Gossamer Bio securities during the class period may be entitled to compensation without any out-of-pocket costs. The deadline to move the Court to serve as lead plaintiff is June 1, 2026. An investor's ability to share in any potential recovery is not dependent on serving as lead plaintiff.
The sharp stock decline brings Gossamer Bio’s market capitalization to just over $40 million, a fraction of its former valuation. The outcome of this litigation will be a critical determinant of the company's future, as it navigates both the legal challenge and the financial fallout from the failed PROSERA study. The next major catalyst for investors will be the court's decision on the lead plaintiff appointment after the June 1 deadline.
This article is for informational purposes only and does not constitute investment advice.
